AG˹ٷ

STOCK TITAN

[424B5] Empire Petroleum Corporation Prospectus Supplement (Debt Securities)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B5
Rhea-AI Filing Summary

Rollins, Inc. (ROL) Form 4: Executive Chairman & Director John F. Wilson sold 30,000 common shares on 07/24/2025 under a pre-arranged Rule 10b5-1 plan at a weighted-average price of $58.04, raising about $1.74 million.

After the sale Wilson still directly owns 632,727 shares (restricted and unrestricted), so the divestiture equals roughly 4.7% of his reported holdings. No derivative securities were involved and his board/executive status is unchanged. The planned nature limits negative signaling, yet investors may view the insider sale as a modest sentiment fade while noting his sizable remaining stake continues to align interests with shareholders.

Rollins, Inc. (ROL) Modulo 4: Il Presidente Esecutivo e Direttore John F. Wilson ha venduto 30.000 azioni ordinarie il 24/07/2025 nell'ambito di un piano predefinito secondo la Regola 10b5-1, a un prezzo medio ponderato di 58,04 dollari, incassando circa 1,74 milioni di dollari.

Dopo la vendita, Wilson possiede ancora direttamente 632.727 azioni (vincolate e libere), quindi la cessione rappresenta circa il 4,7% delle sue partecipazioni dichiarate. Non sono stati coinvolti strumenti derivati e il suo ruolo nel consiglio e come dirigente rimane invariato. La natura pianificata della vendita limita segnali negativi, tuttavia gli investitori potrebbero interpretarla come un leggero calo di fiducia, pur notando che la sua consistente quota residua continua a mantenere allineati gli interessi con quelli degli azionisti.

Rollins, Inc. (ROL) Formulario 4: El Presidente Ejecutivo y Director John F. Wilson vendió 30,000 acciones ordinarias el 24/07/2025 bajo un plan preestablecido conforme a la Regla 10b5-1, a un precio promedio ponderado de $58.04, recaudando aproximadamente $1.74 millones.

Tras la venta, Wilson aún posee directamente 632,727 acciones (restringidas y sin restricciones), por lo que la desinversión representa aproximadamente el 4.7% de sus participaciones reportadas. No se involucraron valores derivados y su estatus en la junta/directiva se mantiene sin cambios. La naturaleza planificada limita señales negativas, aunque los inversores pueden interpretar la venta interna como un leve descenso en el sentimiento, destacando que su considerable participación restante sigue alineando intereses con los accionistas.

Rollins, Inc. (ROL) Form 4: 집행 의장 � 이사 John F. Wilson은 2025� 7� 24� 사전 설정� Rule 10b5-1 계획� 따라 30,000주의 보통주를 가중평� 가� $58.04� 매도하여 � 174� 달러� 조달했습니다.

매도 � Wilson은 여전� 직접 632,727�(제한 � 비제�)� 보유하고 있어, 이번 매각은 그의 신고� 보유 지분의 � 4.7%� 해당합니�. 파생상품은 포함되지 않았으며, 이사� � 임원 지위는 변함이 없습니다. 계획� 매도라는 점에� 부정적 신호� 제한되지�, 투자자들은 내부� 매도� 다소 심리� 약화� � � 있으�, 그의 상당� 잔여 지분이 주주와� 이해관� 일치� 지속한다는 점에 주목� 것입니다.

Rollins, Inc. (ROL) Formulaire 4 : Le Président exécutif et directeur John F. Wilson a vendu 30 000 actions ordinaires le 24/07/2025 dans le cadre d'un plan préétabli selon la règle 10b5-1, à un prix moyen pondéré de 58,04 $, générant environ 1,74 million de dollars.

Après la vente, Wilson détient toujours directement 632 727 actions (restreintes et non restreintes), la cession représentant environ 4,7 % de ses avoirs déclarés. Aucun titre dérivé n’a été impliqué et son statut au sein du conseil/exécutif reste inchangé. Le caractère planifié limite les signaux négatifs, mais les investisseurs peuvent percevoir cette vente d’initié comme un léger repli du sentiment, tout en notant que sa participation restante importante continue d’aligner ses intérêts avec ceux des actionnaires.

Rollins, Inc. (ROL) Formular 4: Executive Chairman und Direktor John F. Wilson verkaufte am 24.07.2025 unter einem vorab vereinbarten Rule 10b5-1 Plan 30.000 Stammaktien zu einem gewichteten Durchschnittspreis von 58,04 USD und erzielte dabei etwa 1,74 Millionen USD.

Nach dem Verkauf besitzt Wilson weiterhin direkt 632.727 Aktien (eingeschränkt und uneingeschränkt), sodass die Veräußerung etwa 4,7 % seiner gemeldeten Bestände entspricht. Es waren keine Derivate beteiligt und sein Status im Vorstand/als Führungskraft bleibt unverändert. Die geplante Natur schränkt negative Signale ein, dennoch könnten Anleger den Insider-Verkauf als leichtes Nachlassen der Stimmung interpretieren, wobei seine beträchtliche verbleibende Beteiligung weiterhin die Interessen mit den Aktionären in Einklang bringt.

Positive
  • Trade executed under Rule 10b5-1, limiting potential information asymmetry and showing proactive compliance.
  • Executive Chairman retains a substantial 632,727-share stake, preserving alignment with shareholder interests.
Negative
  • Insider sale of 30,000 shares (~$1.74 mm) may be interpreted as a slight reduction in confidence.
  • Transaction reduces beneficial ownership by ~4.7%, the first reported sale since prior periods (based on filing history).

Insights

TL;DR: Pre-planned insider sale trims stake by ~5%; limited impact given large residual holding.

The $1.7 mm sale is relatively small versus Wilson’s 632k-share position, suggesting portfolio diversification rather than a strategic shift. Because it was executed via a Rule 10b5-1 plan, information asymmetry concerns are muted, and no other executives filed concurrent sales. The trade alone is unlikely to affect valuation multiples or near-term outlook for ROL, though a series of similar sales could signal lower insider conviction.

TL;DR: Governance-neutral event; compliance with 10b5-1 adds transparency.

The filing demonstrates adherence to SEC best practices: advance trading plan, prompt disclosure, attorney-in-fact signature. Wilson still owns >600k shares, maintaining meaningful skin in the game, which supports shareholder alignment. No red flags on timing or volume relative to average daily trading. Impact classified as routine.

Rollins, Inc. (ROL) Modulo 4: Il Presidente Esecutivo e Direttore John F. Wilson ha venduto 30.000 azioni ordinarie il 24/07/2025 nell'ambito di un piano predefinito secondo la Regola 10b5-1, a un prezzo medio ponderato di 58,04 dollari, incassando circa 1,74 milioni di dollari.

Dopo la vendita, Wilson possiede ancora direttamente 632.727 azioni (vincolate e libere), quindi la cessione rappresenta circa il 4,7% delle sue partecipazioni dichiarate. Non sono stati coinvolti strumenti derivati e il suo ruolo nel consiglio e come dirigente rimane invariato. La natura pianificata della vendita limita segnali negativi, tuttavia gli investitori potrebbero interpretarla come un leggero calo di fiducia, pur notando che la sua consistente quota residua continua a mantenere allineati gli interessi con quelli degli azionisti.

Rollins, Inc. (ROL) Formulario 4: El Presidente Ejecutivo y Director John F. Wilson vendió 30,000 acciones ordinarias el 24/07/2025 bajo un plan preestablecido conforme a la Regla 10b5-1, a un precio promedio ponderado de $58.04, recaudando aproximadamente $1.74 millones.

Tras la venta, Wilson aún posee directamente 632,727 acciones (restringidas y sin restricciones), por lo que la desinversión representa aproximadamente el 4.7% de sus participaciones reportadas. No se involucraron valores derivados y su estatus en la junta/directiva se mantiene sin cambios. La naturaleza planificada limita señales negativas, aunque los inversores pueden interpretar la venta interna como un leve descenso en el sentimiento, destacando que su considerable participación restante sigue alineando intereses con los accionistas.

Rollins, Inc. (ROL) Form 4: 집행 의장 � 이사 John F. Wilson은 2025� 7� 24� 사전 설정� Rule 10b5-1 계획� 따라 30,000주의 보통주를 가중평� 가� $58.04� 매도하여 � 174� 달러� 조달했습니다.

매도 � Wilson은 여전� 직접 632,727�(제한 � 비제�)� 보유하고 있어, 이번 매각은 그의 신고� 보유 지분의 � 4.7%� 해당합니�. 파생상품은 포함되지 않았으며, 이사� � 임원 지위는 변함이 없습니다. 계획� 매도라는 점에� 부정적 신호� 제한되지�, 투자자들은 내부� 매도� 다소 심리� 약화� � � 있으�, 그의 상당� 잔여 지분이 주주와� 이해관� 일치� 지속한다는 점에 주목� 것입니다.

Rollins, Inc. (ROL) Formulaire 4 : Le Président exécutif et directeur John F. Wilson a vendu 30 000 actions ordinaires le 24/07/2025 dans le cadre d'un plan préétabli selon la règle 10b5-1, à un prix moyen pondéré de 58,04 $, générant environ 1,74 million de dollars.

Après la vente, Wilson détient toujours directement 632 727 actions (restreintes et non restreintes), la cession représentant environ 4,7 % de ses avoirs déclarés. Aucun titre dérivé n’a été impliqué et son statut au sein du conseil/exécutif reste inchangé. Le caractère planifié limite les signaux négatifs, mais les investisseurs peuvent percevoir cette vente d’initié comme un léger repli du sentiment, tout en notant que sa participation restante importante continue d’aligner ses intérêts avec ceux des actionnaires.

Rollins, Inc. (ROL) Formular 4: Executive Chairman und Direktor John F. Wilson verkaufte am 24.07.2025 unter einem vorab vereinbarten Rule 10b5-1 Plan 30.000 Stammaktien zu einem gewichteten Durchschnittspreis von 58,04 USD und erzielte dabei etwa 1,74 Millionen USD.

Nach dem Verkauf besitzt Wilson weiterhin direkt 632.727 Aktien (eingeschränkt und uneingeschränkt), sodass die Veräußerung etwa 4,7 % seiner gemeldeten Bestände entspricht. Es waren keine Derivate beteiligt und sein Status im Vorstand/als Führungskraft bleibt unverändert. Die geplante Natur schränkt negative Signale ein, dennoch könnten Anleger den Insider-Verkauf als leichtes Nachlassen der Stimmung interpretieren, wobei seine beträchtliche verbleibende Beteiligung weiterhin die Interessen mit den Aktionären in Einklang bringt.

Supplement No. 2 to Prospectus Supplement dated July 10, 2025, and supplemented on July 24, 2025   Filed Pursuant to Rule 424(b)(5)

(to prospectus dated September 22, 2023)

  Registration Statement No. 333-274327

 

 

 



 

 

 

Subscription Rights to Purchase Up to 33,766,388 Units, Consisting of an Aggregate of

471,698 Shares of Common Stock and Warrants Exercisable for 457,875 Shares of Common Stock

 

 

This supplement no. 2 dated July 25, 2025, or this supplement, supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus supplements dated July 10, 2025 and July 24, 2025, relating to the prior distribution at no charge to the holders of common stock, par value $0.001 per share (“common stock”), of Empire Petroleum Corporation, a Delaware corporation (the “Company,” “we,” “us” or “our”), as of the close of business, on July 10, 2025 (the “Record Date”), subscription rights to purchase up to 33,766,388 units at $0.07367 per unit (the “subscription price”), each unit consisting of 0.0139 shares of common stock and one rights warrant to purchase 0.0136 shares of common stock at $5.46 per whole share, for an aggregate rights offering value of up to $5.0 million, including up to $2.5 million from the exercise of the warrants (the “rights offering”). The Company had previously set the subscription price at $5.30 per unit, but adjusted the subscription price to $0.07367 per unit to more accurately reflect the intended terms of the rights offering.

A stockholder must hold at least 72 shares of common stock to receive subscription rights to purchase at least one whole share at $5.30 per share, as well as at least 74 shares of common stock to receive warrants to purchase one whole share at $5.46 per share. For example, if a stockholder owned 100 shares of our common stock on the record date, the stockholder would be granted subscription rights to purchase an aggregate of 1.39 shares of common stock (rounded down to the nearest whole share) and warrants exercisable for 1.36 shares of common stock (rounded down to the nearest whole share) at the subscription price.

Each stockholder will receive one subscription right for each share of our common stock owned as of the Record Date. Each subscription right entitles the holder of the subscription rights to purchase one unit at the subscription price. We will not issue any fractional units or shares of common stock in the rights offering. The subscription rights are not transferable. If you fully exercise your subscription right and other stockholders do not fully exercise their subscription rights, you will have an over-subscription right to purchase additional units that remain unsubscribed at the Expiration Date (defined below).

This supplement should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection with, the prior prospectus supplements dated July 10, 2025 and July 24, 2025 (including the base prospectus dated September 22, 2023), including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency between the information in the prospectus supplement and this supplement, you should rely on the information in this supplement.

The subscription rights will expire and will have no value if they are not exercised prior to the expiration date of the rights offering, which has been extended to 5:00 p.m. Eastern Time, on August 18, 2025 (the “Expiration Date”), unless we, in our sole discretion, extend the period further for exercising the subscription rights. We have extended the Expiration Date in order to allow our stockholders to have more time to consider their participation and arrange finances for the rights offering. We will extend the duration of the rights offering as required by applicable law and may choose to extend the rights offering further if we decide that changes warrant an extension, as we have done with this prospectus supplement, or if we decide that the degree of participation in the rights offering by holders of our common stock is less than the level we desire. You should carefully consider whether or not to exercise your subscription rights before the Expiration Date. We reserve the right to cancel the rights offering at any time before the Expiration Date, for any reason.

Phil E. Mulacek, Chairman of the Board of the Company (“Mulacek”), owns approximately 21.4% of our common stock outstanding prior to the rights offering. Mulacek has indicated his intent to participate in the rights offering and fully subscribe to the units corresponding to his subscription rights, as well as his intent to fully exercise his over-subscription rights to purchase his pro rata share of the underlying securities related to the rights offering that remain unsubscribed at the Expiration Date.

There is no minimum number of units that we must sell in order to complete the rights offering. If you exercise your subscription rights in full, you will have an over-subscription right to purchase additional units that remain unsubscribed at the Expiration Date, subject to the availability and allocation of units among stockholders exercising their over-subscription rights as further described in this prospectus supplement. Stockholders who do not participate in the rights offering will continue to own the same number of shares, but will own after the rights offering a smaller percentage of the total shares outstanding to the extent that other stockholders participate in the rights offering. Subscription rights that are not exercised before the Expiration Date will expire and have no value.

We have not employed any brokers, dealers or underwriters in connection with the solicitation or exercise of rights in the rights offering and no commissions, fees or discounts will be paid in connection with the rights offering. Securities Transfer Corporation (“STC”) is acting as the subscription and information agent for the rights offering. STC is also transfer agent and registrar for our common stock. While certain of our directors, officers and other employees may solicit responses from you, those directors, officers and other employees will not receive any commissions or compensation for their services other than their normal compensation.

Our common stock is listed on the NYSE American (the “NYSEA”) under the symbol “EP.” On July 24, 2025, the last reported sale price for our common stock on the NYSEA was $4.96 per share. 

 

 

An investment in our common stock involves significant risks. These risks are described under “Risk Factors” beginning on page S-23 of the prospectus supplement dated July 10, 2025 and under similar headings in our filings with the Securities and Exchange Commission (the “SEC”), that are incorporated by reference into this prospectus supplement and the accompanying prospectus. 

Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this prospectus supplement is July 25, 2025

 

 

FAQ

How many Rollins (ROL) shares did John F. Wilson sell?

He sold 30,000 common shares on 07/24/2025.

At what price were the ROL shares sold?

The weighted-average sale price was $58.04, with trades ranging from $58.01 to $58.07.

How many Rollins shares does Wilson still own after the sale?

He beneficially owns 632,727 shares (restricted and unrestricted) following the transaction.

Was the insider sale pre-planned?

Yes. The filing states the trade was made under a Rule 10b5-1 trading plan adopted earlier.

Did the filing report any derivative security activity?

No. No derivative securities were acquired or disposed of in this Form 4.
Empire Petroleum

NYSE:EP

EP Rankings

EP Latest News

EP Latest SEC Filings

EP Stock Data

166.44M
14.40M
56.99%
10.24%
3.85%
Oil & Gas E&P
Crude Petroleum & Natural Gas
United States
TULSA